Search clinical trials for: potentially malignant disorders

Total 149258 results

Proteocyte Diagnostics Inc.
The University of Texas Health Science Center, Houston; University of Alabama... and other collaborators

Recruiting

Evaluation of Oral Potentially Malignant Disorders (OPMDs) With STRATICYTE™

Mouth Diseases

United States
National Cancer Institute (NCI)

Recruiting

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

Fanconi Anemia | Inherited Bone Marrow Failure Syndrome

United States
Universidad Rey Juan Carlos

Recruiting

Predictive Value of GOCCLES® Device for Early Diagnosis of Oral Potentially Malignant Disorders

Oral Cancer | Oral Potentially Malignant Disorders

Spain
Dalarna County Council, Sweden
Uppsala University

Recruiting

Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD) (PMOD)

Mouth Neoplasms

Sweden
University of Milan

Recruiting

Oral Potentially Malignant Disorders: Comparison Between Surgical Treatment and Wait and See Approach

Leukoplakia, Oral

Italy
University of Santiago de Compostela

Recruiting

Role of the Dentist in the Control of the Alcoholic Habit in Patients With Potentially Malignant Oral Lesions (ALCODENT)

Alcohol Drinking | Oral Potentially Malignant Disorders

Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders

Dysplasia | Premalignant Lesion | Lip and Oral Cavity Carcinoma | Oral Disorder

United States
Fayoum University

Completed

Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma

Oral Squamous Cell Carcinoma

Egypt
Institut Pasteur

Completed

Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity (INECOC)

Squamous Cell Carcinoma of the Oral Cavity | Leukoplakia Oral

France
All India Institute of Medical Sciences, New Delhi

Completed

Photographic Evidence of Oral Precancerous Lesions in Current Tobacco and Areca Nut Users Improves Their Quit Rates

Precancerous Conditions

India
University of Zagreb
Croatian Science Foundation

Unknown

Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients (OCSALTM)

Precancerous Lesions | Oral Cavity Squamous Cell Carcinoma | Saliva Altered
National Taiwan University Hospital

Unknown

The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma (p62/SQSTM1)

Oral Cancer | Oral Potentially Malignant Disorder | Malignant Disorder | p62/SQSTM1
Cardarelli Hospital

Not yet recruiting

NBI for Early Diagnosis of OPMD/OSCC (NBI_Oral)

Oral Squamous Cell Carcinoma | Oral Potentially Malignant Disorder

Italy
National Cancer Institute (NCI)

Not yet recruiting

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Undifferentiated Pleomorphic Sarcoma | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Odense University Hospital

Recruiting

OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.

Quality of Life | Pleural Carcinomatosis | Chemotherapy Effect | Pleural Neoplasms | Chemotherapeutic Toxicity | Malignant Pleural Effusion | Pleural Cavity Effusion

Denmark
mAbxience Research S.L.

Recruiting

A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders (MB04-A-01-23)

Healthy Volunteers

Netherlands
University of Milan
University of Turin, Italy

Recruiting

Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life

Glioma | Glioma, Malignant

Italy
Mayo Clinic

Not yet recruiting

Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy

Malignant Brain Neoplasm

United States
Cook Research Incorporated

Not yet recruiting

EchoTip AcuCore Post-Market Clinical Study

Adenocarcinoma | Hepatocellular Carcinoma | Neuroendocrine Tumors | Cholangiocarcinoma | Metastasis | Chronic Pancreatitis | Autoimmune Pancreatitis | Malignant Lymphoma
Mayo Clinic
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Recruiting

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Malignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm

United States
City of Hope Medical Center

Recruiting

Early Detection of Advanced Adenomas and Colorectal Cancer (AACRC)

Colorectal Neoplasms | Colorectal Cancer | Colorectal Disorders | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Adenomatous Polyp | Colorectal Cancer Stage I | Colorectal Adenoma... and other conditions

United States, Italy, China, Spain, Japan
Imperial College London

Not yet recruiting

SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours (SUMMER)

Ovarian Neoplasms | Ovarian Cancer | Ovary Cancer | Germ Cell Tumor | Ovary Neoplasm | Germ Cell Cancer | Germ Cell Ovarian Cancer | Germ Cell Neoplasia
Mayo Clinic

Recruiting

Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy

Malignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm

United States
Section for Affective Disorders; Northern Stockholm...
Karolinska Institutet; Vastra Gotaland Region; Region Örebro County; Uppsala University...

Recruiting

Cancer Related Major Depression Treated With a Single Dose of Psilocybin (CAPSI)

MDD

Sweden
University of Palermo

Recruiting

SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography (SYMILIS OCT)

Oral Disease | Oral Cancer | Actinic Keratoses | Oral Leukoplakia | Oral Squamous Cell Carcinoma | Oral Lichen Planus | Graft-versus-host-disease | Proliferative Verrucous Leukoplakia | Actinic Cheilitis | Oral Potentially Malignant Disorder | Oral Erythroplakia | Oral Lichenoid Lesion

Italy
Norwegian University of Science and Technology
St. Olavs Hospital

Recruiting

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography (TRUST-ACE)

Breast Neoplasm Malignant Primary

Norway
Roswell Park Cancer Institute

Not yet recruiting

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

Malignant Solid Neoplasm

United States
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) (RECSUR)

Glioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, Malignant

United States, Germany, Netherlands, Switzerland, Belgium
Dr Jean Yannis PERENTES

Recruiting

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Mesothelioma, Malignant | Carcinoma Breast Stage IV

Switzerland
National Institute on Aging (NIA)
Brown University

Not yet recruiting

Deprescribing Potentially Inappropriate Medications in the Emergency Department for Persons Living With Dementia (IMPACT)

Dementia

United States
Erasmus Medical Center
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma (RECMAP)

Glioblastoma | Brain Neoplasms | Recurrent Glioblastoma | Recurrent Adult Brain Tumor | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme of Brain | Brain Neoplasms, Adult, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Switzerland, Belgium, Netherlands
Ain Shams University

Recruiting

Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions

Oral Potentially Malignant Lesions

Egypt
Eve Rodler

Not yet recruiting

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Breast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditions

United States
University Hospital, Angers

Not yet recruiting

RAT-HEMATO : Return to Work After Malignant Hemopathy (RAT-HEMATO)

Lymphoma | Leukemia | Multiple Myeloma

France

Search clinical trials for: potentially malignant disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations